Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 151

Results For "SPE"

5007 News Found

ICN to organize virtual discussion on
R&D | June 02, 2025

ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4

Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals


Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer
Clinical Trials | June 02, 2025

Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer

Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer


Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
News | June 02, 2025

Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio


QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
News | May 31, 2025

QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25

Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25


Paras Health Gurugram raises alarm over surge in tobacco-related cancers
News | May 31, 2025

Paras Health Gurugram raises alarm over surge in tobacco-related cancers

Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers


Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
News | May 30, 2025

Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr

The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago


Sudeep Pharma acquires Nutrition Supplies Services
News | May 30, 2025

Sudeep Pharma acquires Nutrition Supplies Services

This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio


Merck withdraws Biologics License Application for Patritumab Deruxtecan
Drug Approval | May 30, 2025

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance


Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer
Drug Approval | May 29, 2025

Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer

This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition


Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Drug Approval | May 29, 2025

Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’

Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA